{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreig3dnmb6lq4yavptqm3ceosjjsfyfztb52o5gkkspiso6gq66brmi",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mltsfvcke772"
  },
  "path": "/2026/05/14/datar-cancer-genetics-receives-landmark-us-fda-clearance-for-celldx-tissue-a-comprehensive-genomic-profiling-assay-for-solid-tumors-using-dna-rna/",
  "publishedAt": "2026-05-14T15:58:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "Clearance Recognises CellDx-Tissue’s Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Level Evidence NASHIK, India, May 14, 2026 /PRNewswire/ — Datar Cancer Genetics (DCG), a global precision oncology company, today announced that its tissue-based comprehensive genomic profiling (CGP) assay for all solid tumors, CellDx-Tissue, has been […]",
  "title": "Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA"
}